László Maródi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
László Maródi has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Melinda Erdős
Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
4 shared publications- Melinda Erdős
Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
3 shared publications Árpád Lányi
Department of Immunology Faculty of Medicine University of Debrecen Debrecen Hungary
3 shared publicationsBertrand Boisson
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publicationsBeáta Tóth
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications- Cristina Tomacinschii
Department of Pediatrics, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova | Institute of Mother and Child, Chisinau, Republic of Moldova
2 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 26 (1) , 1-12
Persistently Elevated Serum IgM: A Diagnostic Red Flag for Primary Immunodeficiencies: A Case-Based Review and Clinical Approach
Introduction/Objective: Persistently elevated serum immunoglobulin M (IgM) is commonly interpreted as a marker of acute infection, autoimmune activity, or lymphoproliferation. Sustained IgM elevation may represent an underrecognized marker of underlying primary immunodeficiency disorders (PIDs), especially those associated with class-switch recombination defects or immune dysregulation. This article aims to highlight the diagnostic value of persistently elevated IgM levels in pediatric PIDs and to propose a practical clinical framework for the evaluation of children with unexplained IgM elevation. Methods: We performed a case-based narrative review of the literature on primary immunodeficiencies associated with elevated serum IgM, focusing on pathogenic mechanisms, clinical phenotypes, and diagnostic implications. The review was complemented by two pediatric cases from our practice in which persistent IgM elevation served as a clue to the diagnosis of distinct primary immunodeficiencies. Results: Persistently increased IgM levels in PIDs may reflect impaired class-switch recombination, impaired germinal center maturation, or chronic immune activation. The two presented cases, ataxiatelangiectasia with a hyper-IgM phenotype and BENTA disease, illustrate how elevated IgM associated with frequent and severe infections, lymphoproliferation, growth impairment, or syndromic features may guide clinicians toward immunological and genetic evaluation. Discussion: Persistent IgM elevation should be interpreted in its clinical context and should not be dismissed as a nonspecific laboratory abnormality. A structured diagnostic approach may help distinguish secondary causes, classic hyper-IgM syndromes, and hyper-IgM phenotypes. Conclusion: Persistently elevated serum IgM should not be dismissed as a transient abnormality in children with recurrent infections or immune dysregulation. When interpreted in its clinical context, it may serve as a practical indicator for further immunological investigation and diagnosis of PIDs.
- 1 August 2026
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 26 (1) , 1-12
Open AccessPersistently Elevated Serum IgM: A Diagnostic Red Flag for Primary Immunodeficiencies: A Case-Based Review and Clinical Approach
Introduction/Objective: Persistently elevated serum immunoglobulin M (IgM) is commonly interpreted as a marker of acute infection, autoimmune activity, or lymphoproliferation. Sustained IgM elevation may represent an underrecognized marker of underlying primary immunodeficiency disorders (PIDs), especially those associated with class-switch recombination defects or immune dysregulation. This article aims to highlight the diagnostic value of persistently elevated IgM levels in pediatric PIDs and to propose a practical clinical framework for the evaluation of children with unexplained IgM elevation. Methods: We performed a case-based narrative review of the literature on primary immunodeficiencies associated with elevated serum IgM, focusing on pathogenic mechanisms, clinical phenotypes, and diagnostic implications. The review was complemented by two pediatric cases from our practice in which persistent IgM elevation served as a clue to the diagnosis of distinct primary immunodeficiencies. Results: Persistently increased IgM levels in PIDs may reflect impaired class-switch recombination, impaired germinal center maturation, or chronic immune activation. The two presented cases, ataxiatelangiectasia with a hyper-IgM phenotype and BENTA disease, illustrate how elevated IgM associated with frequent and severe infections, lymphoproliferation, growth impairment, or syndromic features may guide clinicians toward immunological and genetic evaluation. Discussion: Persistent IgM elevation should be interpreted in its clinical context and should not be dismissed as a nonspecific laboratory abnormality. A structured diagnostic approach may help distinguish secondary causes, classic hyper-IgM syndromes, and hyper-IgM phenotypes. Conclusion: Persistently elevated serum IgM should not be dismissed as a transient abnormality in children with recurrent infections or immune dysregulation. When interpreted in its clinical context, it may serve as a practical indicator for further immunological investigation and diagnosis of PIDs.
- Open Access
- 1 March 2026
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 13 (1) , 23-28
Exploring the clinical spectrum of DiGeorge syndrome
Introduction. DiGeorge syndrome, known also as 22q11.2 deletion syndrome, is a rare multisystemic disorder characterized by a wide range of clinical features and may include thymic aplasia and subsequent immunodeficiency, conotruncal cardiac anomalies, typical facial features, palatal abnormalities, and hypocalcemia due to hypoparathyroidism. Material and methods. Data were collected for 10 patients genetically confirmed with DiGeorge syndrome at the Institute of Mother and Child. This included general information, laboratory results, and clinical features. Results. The mean age at diagnosis was 74.6 months (3 months - 28 years). Most cases were sporadic, with only 2 patients having a history of DGS (n=1), or close relatives with cardiac malformations (n=1). The most common symptoms that led to diagnosis were congenital heart defects (90%), and facial dysmorphism (90%). Common clinical features included recurrent infections (40%) and ENT disorders (20%). Weight was within normal percentiles for the entire group, but a delay in height growth was noted. Regarding the immunological characteristics: lymphopenia was recorded in 20% of patients, and thrombocytopenia in 2 patients. Conclusions. Given the diverse array of symptoms associated with DiGeorge syndrome, physicians should be knowledgeable about both typical and less common characteristics of the syndrome to facilitate optimal treatment and potentially enable early diagnosis.
- 1 March 2026
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 13 (1) , 23-28
Open AccessExploring the clinical spectrum of DiGeorge syndrome
Introduction. DiGeorge syndrome, known also as 22q11.2 deletion syndrome, is a rare multisystemic disorder characterized by a wide range of clinical features and may include thymic aplasia and subsequent immunodeficiency, conotruncal cardiac anomalies, typical facial features, palatal abnormalities, and hypocalcemia due to hypoparathyroidism. Material and methods. Data were collected for 10 patients genetically confirmed with DiGeorge syndrome at the Institute of Mother and Child. This included general information, laboratory results, and clinical features. Results. The mean age at diagnosis was 74.6 months (3 months - 28 years). Most cases were sporadic, with only 2 patients having a history of DGS (n=1), or close relatives with cardiac malformations (n=1). The most common symptoms that led to diagnosis were congenital heart defects (90%), and facial dysmorphism (90%). Common clinical features included recurrent infections (40%) and ENT disorders (20%). Weight was within normal percentiles for the entire group, but a delay in height growth was noted. Regarding the immunological characteristics: lymphopenia was recorded in 20% of patients, and thrombocytopenia in 2 patients. Conclusions. Given the diverse array of symptoms associated with DiGeorge syndrome, physicians should be knowledgeable about both typical and less common characteristics of the syndrome to facilitate optimal treatment and potentially enable early diagnosis.
- Open Access
- 16 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1032358
Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021
Introduction: The J Project (JP) physician education and clinical research collaboration program was started in 2004 and includes by now 32 countries mostly in Eastern and Central Europe (ECE). Until the end of 2021, 344 inborn errors of immunity (IEI)-focused meetings were organized by the JP to raise awareness and facilitate the diagnosis and treatment of patients with IEI.Results: In this study, meeting profiles and major diagnostic and treatment parameters were studied. JP center leaders reported patients’ data from 30 countries representing a total population of 506 567 565. Two countries reported patients from JP centers (Konya, Turkey and Cairo University, Egypt). Diagnostic criteria were based on the 2020 update of classification by the IUIS Expert Committee on IEI. The number of JP meetings increased from 6 per year in 2004 and 2005 to 44 and 63 in 2020 and 2021, respectively. The cumulative number of meetings per country varied from 1 to 59 in various countries reflecting partly but not entirely the population of the respective countries. Altogether, 24,879 patients were reported giving an average prevalence of 4.9. Most of the patients had predominantly antibody deficiency (46,32%) followed by patients with combined immunodeficiencies (14.3%). The percentages of patients with bone marrow failure and phenocopies of IEI were less than 1 each. The number of patients was remarkably higher that those reported to the ESID Registry in 13 countries. Immunoglobulin (IgG) substitution was provided to 7,572 patients (5,693 intravenously) and 1,480 patients received hematopoietic stem cell therapy (HSCT). Searching for basic diagnostic parameters revealed the availability of immunochemistry and flow cytometry in 27 and 28 countries, respectively, and targeted gene sequencing and new generation sequencing was available in 21 and 18 countries. The number of IEI centers and experts in the field were 260 and 690, respectively. We found high correlation between the number of IEI centers and patients treated with intravenous IgG (IVIG) (correlation coefficient, cc, 0,916) and with those who were treated with HSCT (cc, 0,905). Similar correlation was found when the number of experts was compared with those treated with HSCT. However, the number of patients treated with subcutaneous Ig (SCIG) only slightly correlated with the number of experts (cc, 0,489) and no correlation was found between the number of centers and patients on SCIG (cc, 0,174).Conclusions: 1) this is the first study describing major diagnostic and treatment parameters of IEI care in countries of the JP; 2) the data suggest that the JP had tremendous impact on the development of IEI care in ECE; 3) our data help to define major future targets of JP activity in various countries; 4) we suggest that the number of IEI centers and IEI experts closely correlate to the most important treatment parameters; 5) we propose that specialist education among medical professionals plays pivotal role in increasing levels of diagnostics and adequate care of this vulnerable and still highly neglected patient population; 6) this study also provides the basis for further analysis of more specific aspects of IEI care including genetic diagnostics, disease specific prevalence, newborn screening and professional collaboration in JP countries.
- 16 December 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1032358
Open AccessCare of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021
Introduction: The J Project (JP) physician education and clinical research collaboration program was started in 2004 and includes by now 32 countries mostly in Eastern and Central Europe (ECE). Until the end of 2021, 344 inborn errors of immunity (IEI)-focused meetings were organized by the JP to raise awareness and facilitate the diagnosis and treatment of patients with IEI.Results: In this study, meeting profiles and major diagnostic and treatment parameters were studied. JP center leaders reported patients’ data from 30 countries representing a total population of 506 567 565. Two countries reported patients from JP centers (Konya, Turkey and Cairo University, Egypt). Diagnostic criteria were based on the 2020 update of classification by the IUIS Expert Committee on IEI. The number of JP meetings increased from 6 per year in 2004 and 2005 to 44 and 63 in 2020 and 2021, respectively. The cumulative number of meetings per country varied from 1 to 59 in various countries reflecting partly but not entirely the population of the respective countries. Altogether, 24,879 patients were reported giving an average prevalence of 4.9. Most of the patients had predominantly antibody deficiency (46,32%) followed by patients with combined immunodeficiencies (14.3%). The percentages of patients with bone marrow failure and phenocopies of IEI were less than 1 each. The number of patients was remarkably higher that those reported to the ESID Registry in 13 countries. Immunoglobulin (IgG) substitution was provided to 7,572 patients (5,693 intravenously) and 1,480 patients received hematopoietic stem cell therapy (HSCT). Searching for basic diagnostic parameters revealed the availability of immunochemistry and flow cytometry in 27 and 28 countries, respectively, and targeted gene sequencing and new generation sequencing was available in 21 and 18 countries. The number of IEI centers and experts in the field were 260 and 690, respectively. We found high correlation between the number of IEI centers and patients treated with intravenous IgG (IVIG) (correlation coefficient, cc, 0,916) and with those who were treated with HSCT (cc, 0,905). Similar correlation was found when the number of experts was compared with those treated with HSCT. However, the number of patients treated with subcutaneous Ig (SCIG) only slightly correlated with the number of experts (cc, 0,489) and no correlation was found between the number of centers and patients on SCIG (cc, 0,174).Conclusions: 1) this is the first study describing major diagnostic and treatment parameters of IEI care in countries of the JP; 2) the data suggest that the JP had tremendous impact on the development of IEI care in ECE; 3) our data help to define major future targets of JP activity in various countries; 4) we suggest that the number of IEI centers and IEI experts closely correlate to the most important treatment parameters; 5) we propose that specialist education among medical professionals plays pivotal role in increasing levels of diagnostics and adequate care of this vulnerable and still highly neglected patient population; 6) this study also provides the basis for further analysis of more specific aspects of IEI care including genetic diagnostics, disease specific prevalence, newborn screening and professional collaboration in JP countries.
- Open Access
- 8 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 975017
Case Report: Association between cyclic neutropenia and SRP54 deficiency
Autosomal dominant mutations in the signal recognition particle (SRP) 54 gene were recently described in patients with severe congenital neutropenia (SCN). SRP54 deficiency cause a chronic and profound neutropenia with maturation arrest at the promyelocyte stage, occurring in the first months of life. Nearly all reported patients with SRP54 mutations had neutropenia without a cyclic pattern and showed a poor or no response to granulocyte colony-stimulating factor (G-CSF) therapy. We report here an 11-year-old female patient with cyclic neutropenia and recurrent heterozygous p.T117del (c.349_351del) in-frame deletion mutation in SRP54, who showed remarkable therapeutic response to G-CSF treatment. The diagnosis of cyclic pattern of neutropenia was established by acceptable standards. ELANE gene mutation was excluded by using various genetic approaches. The patient described here also had dolichocolon which has not been described before in association with SCN.
- 8 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 975017
Open AccessCase Report: Association between cyclic neutropenia and SRP54 deficiency
Autosomal dominant mutations in the signal recognition particle (SRP) 54 gene were recently described in patients with severe congenital neutropenia (SCN). SRP54 deficiency cause a chronic and profound neutropenia with maturation arrest at the promyelocyte stage, occurring in the first months of life. Nearly all reported patients with SRP54 mutations had neutropenia without a cyclic pattern and showed a poor or no response to granulocyte colony-stimulating factor (G-CSF) therapy. We report here an 11-year-old female patient with cyclic neutropenia and recurrent heterozygous p.T117del (c.349_351del) in-frame deletion mutation in SRP54, who showed remarkable therapeutic response to G-CSF treatment. The diagnosis of cyclic pattern of neutropenia was established by acceptable standards. ELANE gene mutation was excluded by using various genetic approaches. The patient described here also had dolichocolon which has not been described before in association with SCN.
- Open Access
- 1 June 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (6) , e13805
A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project
- 1 June 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (6) , e13805
Open AccessA novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project
- 9 May 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (6) , 1151-1155
A Rose Amongst the Thorns: the Mission of the J Project in a Conflictual World
- 9 May 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (6) , 1151-1155
A Rose Amongst the Thorns: the Mission of the J Project in a Conflictual World
- Open Access
- 30 January 2022
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 163 (5) , 166-170
COVID–19 primer immunhiányos betegekben
Összefoglaló. Az új típusú koronavírus (SARS-CoV-2) okozta pandémia súlyos terhet és nagy kihívást jelent a fertőzésekkel szemben általában is fogékony, szerteágazó immunológiai és genetikai hátterű, primer immundeficiens (PID-) betegek számára. Az eddigi megfigyelések arra utalnak, hogy a SARS-CoV-2-fertőzés és a súlyos COVID–19 mortalitása nem elsősorban az immunológiai alapbetegséggel, hanem sokkal inkább egyéb, a PID talaján megelőzően kialakult (például bronchiectasia, asthma, autoimmun betegség stb.) vagy attól független krónikus társbetegséggel (például diabetes, krónikus szív- és érrendszeri vagy vesebetegség) és szervi károsodással függ össze. A betegek egy kis csoportjában az I. típusú interferon-immunitás zavarát okozhatják génmutációk vagy autoantitestek termelése. A közleményben az eddig közölt adatok alapján beszámolunk a SARS-CoV-2-fertőzés és a COVID–19 lefolyásáról és mortalitásáról PID-betegekben. Orv Hetil. 2022; 163(5): 166–170. Summary. The pandemic caused by the novel coronavirus (SARS-CoV-2) has resulted in tremendous challenges to the management of patients with primary immunodeficiencies (PIDs) representing a wide range of immunological and genetic entities. Preliminary data suggest that patients with PID would be at increased risk of severe disease and mortality from this newly emerged coronavirus. However, morbidity and mortality by SARS-CoV-2 may depend only partly on specific defect of immunity. Most of disease morbidity and mortality has been published to be related to previous damage of organs and tissues that had developed on the bases of PID before contracting SARS-CoV-2 or other, PID-independent disorders. In a small fraction of patients, impaired type I interferon immunity was found to predispose PID patients to severe coronavirus disease. In this review, we provide an update on published data about SARS-CoV-2 infections and COVID–19 in various PIDs. Orv Hetil. 2022; 163(5): 166–170.
- 30 January 2022
- Published by Akademiai Kiado Zrt. in Orvosi Hetilap
- Vol. 163 (5) , 166-170
Open AccessCOVID–19 primer immunhiányos betegekben
Összefoglaló. Az új típusú koronavírus (SARS-CoV-2) okozta pandémia súlyos terhet és nagy kihívást jelent a fertőzésekkel szemben általában is fogékony, szerteágazó immunológiai és genetikai hátterű, primer immundeficiens (PID-) betegek számára. Az eddigi megfigyelések arra utalnak, hogy a SARS-CoV-2-fertőzés és a súlyos COVID–19 mortalitása nem elsősorban az immunológiai alapbetegséggel, hanem sokkal inkább egyéb, a PID talaján megelőzően kialakult (például bronchiectasia, asthma, autoimmun betegség stb.) vagy attól független krónikus társbetegséggel (például diabetes, krónikus szív- és érrendszeri vagy vesebetegség) és szervi károsodással függ össze. A betegek egy kis csoportjában az I. típusú interferon-immunitás zavarát okozhatják génmutációk vagy autoantitestek termelése. A közleményben az eddig közölt adatok alapján beszámolunk a SARS-CoV-2-fertőzés és a COVID–19 lefolyásáról és mortalitásáról PID-betegekben. Orv Hetil. 2022; 163(5): 166–170. Summary. The pandemic caused by the novel coronavirus (SARS-CoV-2) has resulted in tremendous challenges to the management of patients with primary immunodeficiencies (PIDs) representing a wide range of immunological and genetic entities. Preliminary data suggest that patients with PID would be at increased risk of severe disease and mortality from this newly emerged coronavirus. However, morbidity and mortality by SARS-CoV-2 may depend only partly on specific defect of immunity. Most of disease morbidity and mortality has been published to be related to previous damage of organs and tissues that had developed on the bases of PID before contracting SARS-CoV-2 or other, PID-independent disorders. In a small fraction of patients, impaired type I interferon immunity was found to predispose PID patients to severe coronavirus disease. In this review, we provide an update on published data about SARS-CoV-2 infections and COVID–19 in various PIDs. Orv Hetil. 2022; 163(5): 166–170.
- 23 December 2021
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (2) , 433-436
Persistently Increased Anti-cytokine Antibodies Without Clinical Disease in a Boy with APS1 Genotype
- 23 December 2021
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (2) , 433-436
Persistently Increased Anti-cytokine Antibodies Without Clinical Disease in a Boy with APS1 Genotype
- Open Access
- 26 August 2021
- Published by Wiley in European Journal of Immunology
- Vol. 51 (10) , 2364-2366
The 10th anniversary of the world primary immunodeficiency week: A J Project celebration
- 26 August 2021
- Published by Wiley in European Journal of Immunology
- Vol. 51 (10) , 2364-2366
Open AccessThe 10th anniversary of the world primary immunodeficiency week: A J Project celebration
- Open Access
- 24 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 205 (3) , 354-362
Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype
Signal transducer and activator of transcription 3 (STAT-3) gain-of-function (GOF) syndrome is an early-onset monogenic inborn error of immunity characterized by multi-organ autoimmune disorders, growth failure and lymphoproliferation. We describe that STAT-3 GOF syndrome may be presented with hypogammaglobulinemia and recurrent severe upper and lower respiratory tract infections. In addition, the patient had lymphoproliferation, short stature and interstitial lung disease. Chest computerized tomography examinations showed mild bronchiectasis with areas of non-fibrosing alveolar-interstitial disease and maldevelopment of bilateral first ribs. Using Sanger sequencing, we revealed a novel c.508G>C, p.D170H STAT-3 variant affecting the coiled coil domain of STAT-3. Functional studies confirmed that p.D170H was a GOF variant, as shown by increased phosphorylated STAT-3 (pSTAT-3) and STAT-3 transcriptional activity. Our observation suggests that STAT-3 GOF syndrome can manifest in early childhood with hypogammaglobulinemia and recurrent severe respiratory tract infections. We suggest that patients with lymphoproliferation, hypogammaglobulinemia and severe recurrent infections should be screened for STAT-3 variants, even if autoimmune manifestations are missing.
- 24 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 205 (3) , 354-362
Open AccessNovel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype
Signal transducer and activator of transcription 3 (STAT-3) gain-of-function (GOF) syndrome is an early-onset monogenic inborn error of immunity characterized by multi-organ autoimmune disorders, growth failure and lymphoproliferation. We describe that STAT-3 GOF syndrome may be presented with hypogammaglobulinemia and recurrent severe upper and lower respiratory tract infections. In addition, the patient had lymphoproliferation, short stature and interstitial lung disease. Chest computerized tomography examinations showed mild bronchiectasis with areas of non-fibrosing alveolar-interstitial disease and maldevelopment of bilateral first ribs. Using Sanger sequencing, we revealed a novel c.508G>C, p.D170H STAT-3 variant affecting the coiled coil domain of STAT-3. Functional studies confirmed that p.D170H was a GOF variant, as shown by increased phosphorylated STAT-3 (pSTAT-3) and STAT-3 transcriptional activity. Our observation suggests that STAT-3 GOF syndrome can manifest in early childhood with hypogammaglobulinemia and recurrent severe respiratory tract infections. We suggest that patients with lymphoproliferation, hypogammaglobulinemia and severe recurrent infections should be screened for STAT-3 variants, even if autoimmune manifestations are missing.